DIPG-64. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS. (4th December 2020)

• Record Type: Journal Article
• Authors: Przystal*, Justyna M; Yadavilli*, Sridevi; Abadi*, Christina Colman; Yadav, Viveka Nand; Laternser, Sandra; Cosentino, Chiara Cianciolo; Waszak, Sebastian M; Cartaxo, Rodrigo; Biery, Matt; Myers, Carrie; Jayasekara, Samantha; Olson, James M; Filbin, Mariella G; Vitanza, Nicholas A; Cain, Jason; Koschmann#, Carl; Müller#, Sabine; Nazarian#, Javad
• Is Part Of: Neuro-oncology. Volume 22(2020)Supplement 3
• Page Start: iii300
• Page End: iii300
• Publication Date: 2020-12-04
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noaa222.109
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: INTRODUCTION: DMG-ACT (DMG- multi-arm A daptive and C ombinatorial T rial) aims to implement a highly innovative clinical trial design of combinatorial arms for patients with diffuse midline gliomas (DMGs) at all disease stages that is adaptive to pre-clinical data generated in eight collaborating institutions. The goals of the team are to: i) rapidly identify and validate promising drugs for clinical use, and ii) predict biomarkers for promising drugs. METHODS: In vitro (n=15) and in vivo (n=8) models of DMGs across seven institutions were used to assess single and combination treatments with ONC201, ONC206, marizomib, panobinostat, Val-083, and TAK228. In vivo pharmacokinetic assays using clinically relevant dosing of ONC201, ONC206, and panobinostat were performed. Predictive biomarkers for ONC201 and ONC206 were identified using extensive molecular assays including CRISPR, RNAseq, ELISA, FACS, and IHC. RESULTS: Inhibitory concentrations (IC50 ) were established and validated across participating sites. In vivo validation of single and combination drug assays confirmed drug efficacy as increased survival for: ONC201 (p=0.01), ONC206 (p=0.01), ONC201+ONC206 (p=0.02), and ONC201+panobinostat (p=0.01). Marizomib showed toxicity in murine/zebrafish PDXs models. Murine pharmacokinetic analysis showed peak brain levels of ONC201 and ONC206 above pre-clinical IC50 . Molecular testing and analyses of existing drug screen across 537 cancer cell lines validated mitochondrial stress and ATF4 as the main targets induced by ONC201/6. CONCLUSION: Thorough preclinical testing in a multi-site laboratory setting is feasible and identified ONC201 in combination with ONC206 as promising therapeutics for DMGs. Preclinical and correlative-clinical studies are ongoing.